Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 4.54 MB, PDF document
Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.
Original language | English |
---|---|
Article number | 101880 |
Journal | Urology Case Reports |
Volume | 40 |
Number of pages | 4 |
ISSN | 2214-4420 |
DOIs | |
Publication status | Published - 2022 |
- Metanephric adenoma, Tyrosine kinase inhibitor, Oncology, Renal tumour, ADENOMA
Research areas
ID: 290109540